Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T. Iida K, et al. Among authors: nozaki s. Sci Rep. 2024 Jan 30;14(1):2520. doi: 10.1038/s41598-024-53158-1. Sci Rep. 2024. PMID: 38291115 Free PMC article.
Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Nagai T, Naiki T, Iida K, Nozaki S, Etani T, Sugiyama Y, Ando R, Yanase T, Chaya R, Moritoki Y, Kobayashi D, Akita H, Okamura T, Yasui T. Nagai T, et al. Among authors: nozaki s. Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2995-3000. doi: 10.31557/APJCP.2019.20.10.2995. Asian Pac J Cancer Prev. 2019. PMID: 31653146 Free PMC article.
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: nozaki s. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Among authors: nozaki s. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
Sugiyama Y, Naiki T, Tasaki Y, Mimura Y, Etani T, Noda Y, Nozaki S, Shimizu N, Banno R, Nagai T, Isobe T, Ando R, Moritoki Y, Kataoka T, Odagiri K, Aoki M, Gonda M, Yasui T, Hibi Y. Sugiyama Y, et al. Among authors: nozaki s. Oncology. 2023;101(4):224-233. doi: 10.1159/000529203. Epub 2023 Jan 23. Oncology. 2023. PMID: 36689919
461 results